Literature DB >> 19914562

Randomized clinical trials in gastrointestinal stromal tumors.

Peter A Learn1, Jason K Sicklick, Ronald P DeMatteo.   

Abstract

Gastrointestinal (GI) stromal tumor (GIST) is the most common mesenchymal tumor of the GI tract, constituting 80% of all GI mesenchymal tumors and approximately 20% of all small bowel malignancies, excluding lymphomas. This article provides a summary of recent randomized clinical trials of these tumors.

Entities:  

Mesh：

Year:  2010        PMID： 19914562      PMCID： PMC3164338          DOI： 10.1016/j.soc.2009.09.004

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  19 in total

1.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Authors:  George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

2.  Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

Authors:  John R Zalcberg; Jaap Verweij; Paolo G Casali; Axel Le Cesne; Peter Reichardt; Jean-Yves Blay; Marcus Schlemmer; Martine Van Glabbeke; Michelle Brown; Ian R Judson
Journal:  Eur J Cancer       Date:  2005-08       Impact factor: 9.162

3.  A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

Authors:  Jonathan C Trent; Jennifer Beach; Michael A Burgess; Nicholas Papadopolous; Lei L Chen; Robert S Benjamin; Shreyaskumar R Patel
Journal:  Cancer       Date:  2003-12-15       Impact factor: 6.860

4.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

5.  Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas.

Authors:  S C Blair; M M Zalupski; L H Baker
Journal:  Am J Clin Oncol       Date:  1994-12       Impact factor: 2.339

6.  Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Authors:  Ronald P Dematteo; Michael C Heinrich; Wa'el M El-Rifai; George Demetri
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

7.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Authors:  Jean-Yves Blay; Axel Le Cesne; Isabelle Ray-Coquard; Binh Bui; Florence Duffaud; Catherine Delbaldo; Antoine Adenis; Patrice Viens; Maria Rios; Emmanuelle Bompas; Didier Cupissol; Cecile Guillemet; Pierre Kerbrat; Jérome Fayette; Sylvie Chabaud; Patrice Berthaud; David Perol
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

8.  Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.

Authors:  Gary Von Burton; Cathy Rankin; Mark M Zalupski; Glen M Mills; Ernest C Borden; Antman Karen
Journal:  Am J Clin Oncol       Date:  2006-02       Impact factor: 2.339

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Authors:  John H Edmonson; Randolph S Marks; Jan C Buckner; Michelle R Mahoney
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176
View more
  4 in total

Review 1.  Advances in adjuvant therapy of gastrointestinal stromal tumors.

Authors:  K Adekola; M Agulnik
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

2.  Retrospective analysis of prognostic factors affecting the recurrence and disease-free survival following surgical management of gastrointestinal stromal tumors.

Authors:  Kazım Şenol; Gül Dağlar Özdemir; Arif Zeki Akat; Nuri Aydın Kama
Journal:  Turk J Surg       Date:  2020-06-08

3.  In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibody.

Authors:  Cristina A Metildi; Chih-Min Tang; Sharmeela Kaushal; Stephanie Y Leonard; Paolo Magistri; Hop S Tran Cao; Robert M Hoffman; Michael Bouvet; Jason K Sicklick
Journal:  Ann Surg Oncol       Date:  2013-08-14       Impact factor: 5.344

Review 4.  Sarcoma-The standard-bearer in cancer discovery.

Authors:  Jared W Potter; Kevin B Jones; Jared J Barrott
Journal:  Crit Rev Oncol Hematol       Date:  2018-03-29       Impact factor: 6.312
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.